Format

Send to

Choose Destination
Virology. 2016 Feb;489:165-72. doi: 10.1016/j.virol.2015.10.029. Epub 2016 Jan 5.

A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies.

Author information

1
Yisheng Biopharma. Co., Ltd., Beijing, China.
2
Academy of Military Medical Sciences, Changchun, China.
3
National Center for Safety Evaluation of Drugs, Beijing, China.
4
Beijing Institute for Drug Control, Beijing, China.
5
Academy of Military Medical Sciences, Changchun, China. Electronic address: ronglianghu@hotmail.com.
6
Yisheng Biopharma. Co., Ltd., Beijing, China. Electronic address: hui.shao@yishengbio.com.
7
Yisheng Biopharma. Co., Ltd., Beijing, China. Electronic address: lietao.li@gmail.com.

Abstract

Vaccination alone is not sufficiently effective to protect human from post-exposure rabies virus infection due to delayed generation of rabies virus neutralizing antibodies and weak cellular immunity. Therefore, it is vital to develop safer and more efficacious vaccine against rabies. PIKA, a stabilized chemical analog of double-stranded RNA that interacts with TLR3, was employed as adjuvant of rabies vaccine. The efficacy and safety of PIKA rabies vaccine were evaluated. The results showed that PIKA rabies vaccine enhanced both humoral and cellular immunity. After viral challenge, PIKA rabies vaccine protected 70-80% of animals, while the survival rate of non-adjuvant vaccine group (control) was 20-30%. According to the results of toxicity tests, PIKA and PIKA rabies vaccine are shown to be well tolerated in mice. Thus, this study indicates that PIKA rabies vaccine is an effective and safe vaccine which has the potential to develop next-generation rabies vaccine and encourage the start of clinical studies.

KEYWORDS:

Efficacy; PIKA adjuvant; Rabies vaccine; Safety

PMID:
26765968
DOI:
10.1016/j.virol.2015.10.029
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center